Amikacin
Amikacin safe, improves respiratory symptoms in M. avium complex lung disease
SAN DIEGO — Amikacin for 6 months improved respiratory symptoms in adults with newly diagnosed or recurrent Mycobacterium avium complex lung disease, according to a presentation at the American Thoracic Society International Conference.
Inhaled amikacin lowers incidence of ventilator-associated pneumonia
Fewer critically ill adults who received inhaled amikacin vs. placebo for 3 days developed ventilator-associated pneumonia by day 28, according to results published in The New England Journal of Medicine.
Inhalation therapy containing manuka honey, amikacin shows promise for respiratory infections
Combining manuka honey and the antibiotic amikacin in a lab-based nebulization formulation was effective for inhibiting Mycobacterium abscessus and drug-resistant clinical isolates in patients with cystic fibrosis or bronchiectasis.
Amikacin confers no new safety concerns in Mycobacterium avium complex lung disease
No new safety signals were found with the use of amikacin liposome inhalation suspension added to guideline-based therapy for patients with refractory Mycobacterium avium complex lung disease, according to researchers.